TALARIS THERAPEUTICS INC (TALS)
US87410C1045 - Common Stock
Talaris shareholders approve merger, 1-for-10 reverse stock split (TALS)
Talaris Therapeutics shareholders have approved a merger with Tourmaline Bio and a 1-for-10 reverse stock split to be conducted just prior to the closing. Read more here.
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
Combined Company to Trade on Nasdaq Under Ticker “TRML”Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE...
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APRN, RENB, TALS, WMC
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, TALS, QUOT
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOT
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, TALS, QUOT, CFMS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, NETI, TALS, QUOT
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DICE, QUOT, TALS, CFMS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETI
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (Nasdaq – TALS)
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:POAI),(NASDAQ:AGLE),(NASDAQ:TALS),(NASDAQ:MRTX) EQNX::TICKER_END
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs
/PRNewswire/ -- Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other...
TALS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Talaris Therapeutics, Inc. Is Fair to Shareholders
Talaris stock to merge with Tourmaline Bio in all-stock deal
Cell therapy company Talaris Therapeutics (TALS) and privately-owned Tourmaline Bio announced an agreement on Thursday to combine in an all-stock deal. Read more here.
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye...
Talaris Therapeutics appoints current CFO Mary Kay as interim CEO (NASDAQ:TALS)
Talaris Therapeutics (TALS) put its CFO in charge on Friday, replacing a CEO Scott Requadt, who will be leaving the Company as part of a planned workforce reduction, as...
Talaris Therapeutics Announces Leadership Transition
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay...